methods for screening test compounds capable of antagonizing il-17f signaling, to diagnose a disorder related to increased il-17f signaling in an individual, in vitro to inhibit at least one activity associated with il-21 signaling, in vitro to inhibit at least one activity associated with il-23 signaling, to purify the natural il-17a protein, and to isolate il-17a / il-17f heterodimers substantially free of il-17a homodimers and il-17f, use of a therapeutically effective amount of an il-17f signaling antagonist, pharmaceutical composition, vaccine adjuvant, isolated antibody, isolated il-17f and il-17a proteins, and il-17a / il-heterodimer. 17f

摘要

METHODS FOR MAKING TEST COMPOUNDS ABLE TO ANTAGONIZE IL-17F SIGNALING TO DIAGNOSE AN INCREASED IL-17F SIGNALING DISORDER IN AN INDIVIDUAL, IN VITRO TO INHIBIT AT LEAST 21 SENSITION ACTIVITY IN VITRO TO INHIBIT AT LEAST ONE ACTIVITY ASSOCIATED WITH IL-23 SIGNALING, TO PURIFY NATURAL IL-17A PROTEIN, AND TO INSULATE HETERODYMERS FROM IL-17A / IL-17F SUBSTANTIALLY FREE FROM HOMODYMERS AND IL-17AMS. IL-17F, USE OF A THERAPEUTICALLY EFFICIENT QUANTITY OF AN IL-17F SIGNALING ANTAGONIST, PHARMACEUTICAL COMPOSITION, VACCINE ISOLATED ANTIBODY, IL-17F AND IL-17A ISOLATED PROTEINS 17F. The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A / IL-17F heterodimers and methods for isolating and purifying IL-17 family members, including IL-17A / IL-17F heterodimers of a natural source. The present invention is also directed to novel methods for diagnosing, predicting, monitoring progress and treating and / or preventing IL-17F signaling disorders, i.e., IL-17F-associated disorders, including, but not limited to. , inflammatory disorders, such as autoimmune diseases (eg, arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus and multiple sclerosis), respiratory diseases (eg, COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection) and inflammatory bowel diseases or disorders (IBDs, eg, ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutic products and therapeutic targets and methods for screening and evaluating test compounds for intervention (treatment) and prevention of IL-17F signaling related disorders.